亚太地区神经生物标志物市场预测至 2027 年 - COVID-19 影响和按产品进行区域分析（蛋白质组学生物标志物、基因组学生物标志物、代谢组学生物标志物、成像生物标志物等）；应用（阿尔茨海默病、帕金森病、精神分裂症、亨廷顿病、脊髓性肌萎缩症等）；最终用户（制药和生物技术公司、临床诊断、研究组织）和国家/地区
No. of Pages: 89 | Report Code: TIPRE00020136 | Category: Life Sciences
No. of Pages: 89 | Report Code: TIPRE00020136 | Category: Life Sciences
神经生物标志物是存在于脑脊液 (CSF) 或血液中的分子，支持大脑诊断疾病并监测疾病进展。这有助于疾病的前期检测、微创诊断、加快药物开发速度，有望成为有效的治疗方法。
预计到 2027 年，美国亚太神经生物标志物市场将达到 26.2063 亿美元2019年9.2705亿美元；预计 2020 年至 2027 年复合年增长率为 14.1%。市场的增长归因于关键驱动因素，例如神经系统疾病患病率上升以及对神经系统生物标志物研究的日益关注。另一方面，与生物标志物的使用相关的担忧，例如缺乏预分析测试，是阻碍市场增长的主要因素。
亚太神经生物标志物市场根据产品细分为蛋白质组生物标志物、基因组学生物标志物、代谢组学生物标志物、成像生物标志物等。 2019年，基因组生物标志物领域占据了最大的市场份额。此外，预计同一细分市场的市场在预测期内将以最快的速度增长。
根据应用，亚太神经系统生物标志物市场分为阿尔茨海默病、帕金森病、精神分裂症、亨廷顿病、脊髓性肌萎缩症等。阿尔茨海默病细分市场在 2019 年占据最大的市场份额，预计该细分市场的市场将在 2020 年至 2027 年期间大幅增长。
按最终用户划分，亚太地区神经生物标志物市场分为制药和生物技术公司、临床诊断和研究组织。 2019年，制药和生物技术公司细分市场占据最大份额。此外，预计2020年至2027年同一细分市场的市场将以最快的速度增长。
<强>主要来源和上市公司
与本亚洲报告相关的一些主要和二手来源太平洋神经生物标志物市场包括疾病控制与预防中心 (CDC)、世界卫生组织 (WHO) 和跨神经退行性疾病生物标志物 (BAND)。
< /span>
按产品
< ul type=\"disc\">
按应用
按最终用户
按国家/地区
< strong>公司简介
Strategic insights for Asia Pacific Neurological Biomarker involve closely monitoring industry trends, consumer behaviours, and competitor actions to identify opportunities for growth. By leveraging data analytics, businesses can anticipate market shifts and make informed decisions that align with evolving customer needs. Understanding these dynamics helps companies adjust their strategies proactively, enhance customer engagement, and strengthen their competitive edge. Building strong relationships with stakeholders and staying agile in response to changes ensures long-term success in any market.
| Report Attribute | Details |
|---|---|
| Market size in 2019 | US$ 927.05 Million |
| Market Size by 2027 | US$ 2,620.63 Million |
| Global CAGR (2020 - 2027) | 14.1% |
| Historical Data | 2017-2018 |
| Forecast period | 2020-2027 |
| Segments Covered |
By 产品
|
| Regions and Countries Covered | 亚太地区
|
| Market leaders and key company profiles |
The regional scope of Asia Pacific Neurological Biomarker refers to the geographical area in which a business operates and competes. Understanding regional nuances, such as local consumer preferences, economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved regions or adapting their offerings to meet regional demands. A clear regional focus allows for more effective resource allocation, targeted marketing, and better positioning against local competitors, ultimately driving growth in those specific areas.
The Asia Pacific Neurological Biomarker Market is valued at US$ 927.05 Million in 2019, it is projected to reach US$ 2,620.63 Million by 2027.
As per our report Asia Pacific Neurological Biomarker Market, the market size is valued at US$ 927.05 Million in 2019, projecting it to reach US$ 2,620.63 Million by 2027. This translates to a CAGR of approximately 14.1% during the forecast period.
The Asia Pacific Neurological Biomarker Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Asia Pacific Neurological Biomarker Market report:
The Asia Pacific Neurological Biomarker Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The Asia Pacific Neurological Biomarker Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the Asia Pacific Neurological Biomarker Market value chain can benefit from the information contained in a comprehensive market report.
Office No. 1011, First floor, Farena Corporate Park, Magarpatta-Mundhwa road, Pune - 411028, Maharashtra, India
US:+16467917070
sales@businessmarketinsights.com
Get Free Sample For Asia Pacific Neurological Biomarker Market
